September 25, 2014

Final Stargardt Patient Treated In Initial Stem Cell Trial

Posted in: Latest News

Advanced Cell Technology (ACT) has treated the final patient in the UK-based Phase 1 clinical trial evaluating the safety and tolerability of the company’s stem cell therapy for Stargardt’s disease. To date, no adverse events have been reported. The company is working with U.S. and European regulators to commence a Phase 2 trial to assess the safety and efficacy of stem cell therapy in patients with Stargardt disease and dry age-related macular degeneration.

Read the company’s press release for more information.

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann